Autologous Matrix-induced Chondrogenesis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Autologous Matrix-induced Chondrogenesis Market is Segmented by Material (Hyaluronic Acid, Collagen, Polyethylene Glycol (PEG), Poly lactic-co-glycolic Acid (PLGA), and Other Materials), Application (Knee Cartilage, Elbow Cartilage, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments.

Autologous Matrix-induced Chondrogenesis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Autologous Matrix-induced Chondrogenesis Market Size

Autologous Matrix-induced Chondrogenesis Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 8.10 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Autologous Matrix-induced Chondrogenesis Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Autologous Matrix-induced Chondrogenesis Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Autologous Matrix-induced Chondrogenesis Market Analysis

The Autologous Matrix-induced Chondrogenesis Market is expected to register a CAGR of 8.1% during the forecast period.

  • COVID-19 severely impacted the autologous matrix-induced chondrogenesis market, as many orthopedic surgeries were canceled or delayed to reduce the spread of infection during the early period of the pandemic. For instance, an article published in the Medicine journal in September 2022 revealed that authorities in many countries postponed hip and knee replacement surgeries to prevent the virus from spreading. In the United States, this resulted in the cancellation of 33 thousand primary hip and knee replacements every week until 2020, with roughly 130 thousand surgeries rescheduled. As a result, COVID-19 had a significant impact on the autologous matrix-induced chondrogenesis market. However, with the resumption of operations and a decrease in COVID-19 instances, the market is predicted to recover from the COVID-19 reduction over the forecast period.
  • The rising prevalence of bone and joint disorders, increasing sports and other injuries, and growing demand for minimally invasive procedures are some of the factors driving market growth. Knee and hip replacement surgeries have increased globally in recent years, with persistent wound drainage being a well-known complication that commonly leads to wound development. The increase in surgical procedures is expected to drive demand for the autologous matrix-induced chondrogenesis market. For example, as per the June 2022 report of the Canadian Institute of Health Information, approximately 110 thousand joint replacements were performed in 2020-2021, and more than 7.3 thousand were performed as day surgery, representing a four-fold increase from the previous year, which is expected to drive the growth of the market segment.
  • Furthermore, research studies demonstrating the advantages offered by autologous matrix-induced chondrogenesis are likely to increase opportunities for market growth. For instance, an article published in June 2022 in PubMed revealed that AMIC is useful for treating focal chondral abnormalities in the knee. Moreover, AMIC demonstrated a higher International Knee Documentation Committee (IKDC), a lower visual analog scale (VAS) value, and a lower rate of revision compared to microfracture (MFx). Similarly, an article published in November 2022 in PubMed revealed that according to the main findings of the study, the AMIC technique could be effective in improving symptoms and function in patients with osteochondral lesions (OCLs) of the talus. Statistically significant decreases in pain and enhancements of ankle function (AOFAS/FFI) were observed. Thus, such research studies demonstrate the advantages offered by autologous matrix-induced chondrogenesis and are likely to fuel market growth.
  • However, the lack of a proper reimbursement system and the scarcity of skilled professionals are expected to hinder market growth. Overall, due to the rise in the prevalence of bone and joint disorders and the increase in research studies depicting the advantages of autologous matrix-induced chondrogenesis, the studied market is likely to witness notable growth over the forecast period.

Autologous Matrix-induced Chondrogenesis Industry Overview

The autologous matrix-induced chondrogenesis market is consolidated and consists of a few major players. Companies like Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun SE, CartiHeal, Geistlich Group (Geistlich Pharma AG), JRL Orthopaedic Ltd, Matricel GmbH, Smith+Nephew, Zimmer Biomet Holdings, among others, hold the substantial market share in the market.

Autologous Matrix-induced Chondrogenesis Market Leaders

  1. Anika Therapeutics, Inc.

  2. Arthro-Kinetics

  3. JRL Orthopaedic Ltd

  4. Geistlich Group (Geistlich Pharma AG)

  5. B. Braun SE

  6. *Disclaimer: Major Players sorted in no particular order
Autologous Matrix-induced Chondrogenesis Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Autologous Matrix-induced Chondrogenesis Market News

  • October 2022: Collagen Matrix, Inc. and Linden Capital Partners acquired BV Polyganics, a medical technology company that develops and manufactures bioresorbable medical devices. The acquisition expands Collagen Matrix's portfolio of bioresorbable solutions and technology platforms for bone and tissue repair, unlocking new markets and clinical opportunities for the Company.
  • May 2022: Collagen-based solutions provider Rousselot showcased its latest Colartix ingredient, a collagen matrix from natural cartilage for joint care, at Vitafoods Europe 2022. The ingredient made from naturally occurring collagen peptides and glycosaminoglycans (GAGs) was recently shown in a 'real life' study to steadily decrease joint discomfort across demographics.

Autologous Matrix-induced Chondrogenesis Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Bone and Joint Disorders
    • 4.2.2 Increasing Number of Sports and Other Injuries
    • 4.2.3 Growing Demand for Minimally Invasive Procedures
  • 4.3 Market Restraints
    • 4.3.1 Lack of Proper Reimbursement System
    • 4.3.2 Scarcity of Skilled Professionals and Sufficient Clinical Data
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Material
    • 5.1.1 Hyaluronic Acid
    • 5.1.2 Collagen
    • 5.1.3 Polyethylene Glycol (PEG)
    • 5.1.4 Poly Lactic-co-glycolic Acid (PLGA)
    • 5.1.5 Other Materials
  • 5.2 By Application
    • 5.2.1 Knee Cartilage
    • 5.2.2 Elbow Cartilage
    • 5.2.3 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anika Therapeutics, Inc.
    • 6.1.2 Arthro-Kinetics
    • 6.1.3 B. Braun SE
    • 6.1.4 CartiHeal
    • 6.1.5 Geistlich Group (Geistlich Pharma AG)
    • 6.1.6 JRI Orthopaedics
    • 6.1.7 Matricel GmbH
    • 6.1.8 Smith+Nephew
    • 6.1.9 Zimmer Biomet Holdings
    • 6.1.10 CONMED Corporation
    • 6.1.11 Arthrex
    • 6.1.12 Vericel
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Autologous Matrix-induced Chondrogenesis Industry Segmentation

As per the scope of the report, AMIC is a single-stage cartilage regeneration approach in which a cell-free collagen matrix is implanted into a defective cartilage, combined with microfracture. These treatments have proven better outcomes as compared to conventional techniques.

The autologous matrix-induced chondrogenesis market is segmented by material (hyaluronic acid, collagen, polyethylene glycol (PEG), poly lactic-co-glycolic acid (PLGA), and other materials), application (knee cartilage, elbow cartilage, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (in USD) for the above segments.

By Material Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-co-glycolic Acid (PLGA)
Other Materials
By Application Knee Cartilage
Elbow Cartilage
Other Applications
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Autologous Matrix-induced Chondrogenesis Market Research FAQs

What is the current Autologous Matrix-induced Chondrogenesis Market size?

The Autologous Matrix-induced Chondrogenesis Market is projected to register a CAGR of 8.1% during the forecast period (2025-2030)

Who are the key players in Autologous Matrix-induced Chondrogenesis Market?

Anika Therapeutics, Inc., Arthro-Kinetics, JRL Orthopaedic Ltd, Geistlich Group (Geistlich Pharma AG) and B. Braun SE are the major companies operating in the Autologous Matrix-induced Chondrogenesis Market.

Which is the fastest growing region in Autologous Matrix-induced Chondrogenesis Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Autologous Matrix-induced Chondrogenesis Market?

In 2025, the North America accounts for the largest market share in Autologous Matrix-induced Chondrogenesis Market.

What years does this Autologous Matrix-induced Chondrogenesis Market cover?

The report covers the Autologous Matrix-induced Chondrogenesis Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Autologous Matrix-induced Chondrogenesis Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Autologous Matrix-induced Chondrogenesis Industry Report

Statistics for the 2025 Autologous Matrix-induced Chondrogenesis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Autologous Matrix-induced Chondrogenesis analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.